Summary
Citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline are selective serotonin reuptake inhibitors (SSRIs), which are thought to act as antidepressants through their ability to inhibit presynaptic serotonin reuptake in the brain. The elimination of the SSRIs proceeds predominantly via oxidation catalyzed by cytochrome P450 in the liver. Paroxetine and fluoxetine are potent inhibitors of cytochrome P4502D6 and hence may cause serious interactions with drugs metabolized by this isozyme, notably tricyclic antidepressants, some neuroleptics, and some antiarrhythmics. Citalopram, fluvoxamine and sertraline do not share this property. Fluvoxamine is the only SSRI that is a potent inhibitor of cytochrome P4501A2 and hence causes serious pharmacokinetic interactions with amitriptyline, clomipramine, imipramine, theophylline, and presumably caffeine and other drugs which are metabolized by the isozyme. Citalopram and fluoxetine are administered as racemates, but practically nothing is known about the stereoselective metabolism of the two drugs. Citalopram is partially metabolized via the mephenytoin oxidation polymorphism, and paroxetine is partially metabolized via the sparteine/debrisoquine oxidation polymorphism. The pharmacogenetic differences in the oxidation of the SSRIs themselves are probably of no clinical relevance.
Similar content being viewed by others
Abbreviations
- CYP:
-
cytochrome P450
- EM:
-
extensive metabolizer
- PM:
-
poor metabolizer
- SSRI:
-
selective serotonin reuptake inhibitor
References
Bergstrom RF, Peyton AL, Lemberger L (1992) Quantification and mechanism of the fluoxetine tricyclic antidepressant interaction. Clin Pharmacol Ther 51:239–248
Bertschy G, Vandel S, Vandel B, Allers G, Volmat R (1991) Fluvoxamine-tricyclic antidepressant interaction. Eur J Clin Pharmacol 40:119–120
Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT (1992) The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 33:521–523
Brøsen K, Gram LF (1989) Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36:537–547
Brøsen K, Skjelbo E (1992) Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 — the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 32:136–137
Brøsen K, Gram LF, Kragh-Sørensen (1991) Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine and mephenytoin. Ther Drug Monit 13:177–182
Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44:349–355
Brosen K, Sindrup SH, Skjelbo E, Nielsen KK, Gram LF (1993) Role of genetic polymorphism in psychopharmacology — an update. In: Gram LF, Balant LP, Meltzer HY, Dahl SG (eds) Clinical pharmacology in psychiatry: strategies in drug development. Psychopharmacology series. Springer, Berlin Heidelberg New York, pp 199–211
Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211–1214
Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262–265
Diot P, Jonville AP, Gerard F, Bonelle M, Autret E, Breteau M, Lemarie E, Lavadier M (1991) Possible interaction entre theophylline et fluvoxamine. Therapie 46:170–171
Fuller RW, Snoddy HD, Krushinski JH, Robertson DW (1992) Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 31:997–1000
Gram LF, Hansen MGJ, Sindrup SH, Brøsen K, Poulsen JH, Aaes-Jørgensen T, Overø KF (1993) Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 15:18–24
Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529–532
Hyttel J, Bogeso KP, Perregaard J, Sánchez C(1992) The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Transm 88:157–160
Lemoine A, Gautier JC, Azoulay D, Kiffel L, Guengerich FP, Beaune P, Maurel P, Leroux JP (1993) The major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 43:827–832
Nebert WD, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Loper JC, Sato R, Waterman MR, Waxman DJ (1991) The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 10:1–14
Otton SV, Dafang W, Joffe RT, Cheung SW, Sellers EM (1993). Inhibition by fluoxetine of cytochrome P4502D6 activity. Clin Pharmacol Ther 53:401–409
Preskorn SH, Aldeman J, Messig M, Harris S, Ching M (1992) Desipramine levels after sertraline or fluoxetine. Presented at the American Psychiatric Association Meeting, May 1992, USA
Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF (1990) The selective serotonin inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42:135–144
Sindrup SH, Brosen K, Gram LF (1992) Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: non-linearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:288–295
Sindrup SH, Brosen K, Gram L, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussmann BD (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:278–287
Sindrup SH, Brosen K, Hansen MGJ, Aaes-Mogensen T, Overø KF, Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15:11–17
Skjelbo E, Brosen K, Hallas J, Gram LF (1991) The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 49:18–23
Skjelbo E, Brosen K (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34:256–261
Sperber AD (1991) Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety 6:460–462
Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP (1992) Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 14:194–196
Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP (1993) Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15:243:246
Thomson AH, McGovern EM, Bennie P, Caldwell G, Smith M (1992) Interaction between fluvoxamine and theophylline. Pharm J, vol 137
Torok-Both GA, Baker GB, Coutts RT, McKenna KF, Aspeslet LJ (1992) Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J Chromatogr 579:99–106
van Harten J (1993) Clinical pharmacokinetics of selective serotonin Reuptake inhibitors. Clin Pharmacokinet 24:203–220
Vandel S, Bertschy G, Bonin B, Nezelof S, Francois TH, Vandel B, Sechter D, Bizouard P (1992) Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 25:202–207
Vaughan DA (1988) Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 145:1478
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brøsen, K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 71, 1002–1009 (1993). https://doi.org/10.1007/BF00180032
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00180032